G Medical Innovations Holdings Ltd. Announces Pricing of $15.0 Million Initial Public Offering and Nasdaq Listing
TEL AVIV and NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) — G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the “Company”), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced the pricing of an underwritten initial public offering of 3,000,000 units, each consisting of one ordinary share and one warrant to purchase one ordinary share, at a combined public offering price of $5.00 per unit for aggregate gross proceeds of approximately $15.0 million, prior to deducting underwriting discounts, commissions, and other offering expenses and excluding any exercise of the underwriters’ option to purchase any additional securities as described herein. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 450,000 units at the public offering price less the underwriting discounts and commissions. The offering is expected to close on or about June 29, 2021, subject to satisfaction of customary closing conditions.
The Company has received approval to list its common stock and warrants on the Nasdaq Capital Market under the symbols “GMVD” and “GMVDW”, respectively, with trading expected to begin on June 25, 2021. Each warrant is exercisable for one ordinary share at an exercise price of $6.25 per share and will expire four years from the date of issuance.
EF Hutton, division of Benchmark Investments, LLC, is acting as sole book-running manager for the offering.
The Securities and Exchange Commission (“SEC”) declared effective a registration statement on Form F-1 (File No. 333-253852) relating to these securities on June 24, 2021. A final prospectus relating to this offering will be filed with the SEC. The offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: EF Hutton, division of Benchmark Investments, LLC, 590 Madison Avenue, 39th Floor, New York, NY, 10022, Attention: Syndicate Department, or via email at syndicate@efhuttongroup.com or telephone at (212) 404-7002.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About G Medical Innovations Holdings Ltd.
G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services.
Forward-Looking Statements
This press release contains statements that constitute “forward-looking statements,” including with respect to the Company’s initial public offering, the expected timing of the closing of the offering, the possible offering of additional units, and the intended use of proceeds. No assurance can be given that the offering will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
G Medical Innovations Holdings Ltd. Company Contact
Brendan Dekauwe, Director
brendan@gmedinnovations.com
